In biopharmaceutical manufacturing, whether for mAbs, ADCs, mRNA, or gene therapy products, the GMP grade of chromatography media and buffer raw materials directly determines fileability, traceability, and final drug quality. This article outlines 4 selection dimensions from a regulatory perspective.

Dimension 1: Regulatory compliance

FDA, EMA, and NMPA all require critical raw materials to have: DMF/ASMF files, complete supplier audit reports, batch release records. For products entering BLA/NDA stages, chromatography media suppliers must provide TSE/BSE statements, residual testing reports, and stability data.

Dimension 2: Batch consistency

Inter-batch CV < 2% is the industry gold standard; 3% is the red line. Zechin Bio's AG1200LE agarose passes 6 QC stages (raw material screening → gel formation → EEO → strength → endotoxin → microbiology). Every batch ships with COA + SDS-PAGE, with 50-batch retrospective CV = 1.2%.

Dimension 3: Traceability

Each batch has a unique ID recording raw material lot, production date, equipment, operator, QC report, retention location, and customer flow. Retention samples stored 5 years by default, aligned with post-marketing surveillance cycles.

Dimension 4: Supply chain resilience

For critical raw materials, recommend at least 2 qualified suppliers. Zechin Bio's core products are 100% domestic in raw materials, production, and QC, with no single point of dependency, ready for supply chain risks from international trade friction.

For projects entering IND filing, Zechin Bio offers free compliance support packages (DMF files, audit reports, stability data) — contact your sales engineer.